CARMIEL, Israel, Sept. 18, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced the closing of its offering of $69 million principal amount of its 4.50% Convertible Notes due 2018 (the "Notes") through a private offering, including $9 million aggregate principal amount of Notes related to the initial purchaser's over-allotment option, which was exercised in full.
Help employers find you! Check out all the jobs and post your resume.
